Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop
Seattle Genetics and Genmab, a Danish biotechnology company, announced a 24% response rate for their joint cervical cancer medication tisotumab vedotin, paving the way for potential accelerated FDA approval.